Travere Therapeutics (TVTX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
233.2M
Gross Profit
225.4M
96.68%
Operating Income
-321.4M
-137.83%
Net Income
-321.5M
-137.90%
EPS (Diluted)
-$4.08
Balance Sheet Metrics
Total Assets
594.2M
Total Liabilities
535.0M
Shareholders Equity
59.1M
Debt to Equity
9.06
Cash Flow Metrics
Operating Cash Flow
-194.1M
Free Cash Flow
-338.7M
Revenue & Profitability Trend
Travere Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 233.2M | 145.2M | 109.5M | 131.8M | 198.3M |
| Cost of Goods Sold | 7.7M | 11.4M | 4.4M | 3.8M | 6.1M |
| Gross Profit | 225.4M | 133.8M | 105.0M | 128.0M | 192.2M |
| Operating Expenses | 546.8M | 510.5M | 424.9M | 327.4M | 271.2M |
| Operating Income | -321.4M | -376.7M | -319.8M | -199.4M | -75.4M |
| Pre-tax Income | -320.5M | -376.1M | -331.2M | -216.9M | -188.8M |
| Income Tax | 120.0K | 223.0K | 313.0K | 409.0K | -19.4M |
| Net Income | -321.5M | -111.4M | -278.5M | -180.1M | -169.4M |
| EPS (Diluted) | -$4.08 | -$1.50 | -$4.37 | -$3.01 | -$3.56 |
Income Statement Trend
Travere Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 416.7M | 616.8M | 486.4M | 582.8M | 410.4M |
| Non-Current Assets | 177.5M | 172.2M | 186.2M | 193.8M | 197.0M |
| Total Assets | 594.2M | 789.0M | 672.6M | 776.6M | 607.4M |
| Liabilities | |||||
| Current Liabilities | 200.8M | 177.9M | 142.2M | 124.1M | 92.7M |
| Non-Current Liabilities | 334.3M | 410.2M | 487.6M | 350.4M | 303.6M |
| Total Liabilities | 535.0M | 588.1M | 629.7M | 474.5M | 396.2M |
| Equity | |||||
| Total Shareholders Equity | 59.1M | 200.8M | 42.9M | 302.1M | 211.2M |
Balance Sheet Composition
Travere Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -320.6M | -376.3M | -331.5M | -217.3M | -169.4M |
| Operating Cash Flow | -194.1M | -338.6M | -285.7M | -94.0M | -45.4M |
| Investing Activities | |||||
| Capital Expenditures | - | -668.0K | -191.0K | -5.1M | -6.8M |
| Investing Cash Flow | 200.5M | -110.0M | -4.2M | -118.6M | 51.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 132.6M | 189.1M | 112.5M | 222.8M | 121.8M |
| Free Cash Flow | -338.7M | -322.3M | -214.8M | -38.9M | -162.6M |
Cash Flow Trend
Travere Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.71
Forward P/E
-12.49
Price to Book
41.19
Price to Sales
4.95
PEG Ratio
-12.49
Profitability Ratios
Profit Margin
-82.88%
Operating Margin
-52.21%
Return on Equity
-422.66%
Return on Assets
-23.21%
Financial Health
Current Ratio
2.05
Debt to Equity
1,220.07
Beta
0.74
Per Share Data
EPS (TTM)
-$2.78
Book Value per Share
$0.37
Revenue per Share
$3.35
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| tvtx | 1.4B | -3.71 | 41.19 | -422.66% | -82.88% | 1,220.07 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 59.1B | 13.92 | 1.97 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.7B | -33.90 | 4.41 | -5.86% | -6.48% | 114.67 |
| Agios | 2.1B | 3.17 | 1.44 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.